Intangible assets that are subject to amortization consisted of the following at December 31, 2025 and 2024:


	December 31, 2025							December 31, 2024
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trade name	$	1,000,000	$	(842,000	)	$	158,000	$	1,000,000	$	(642,000	)	$	358,000
Customer relationships		3,000,000		(2,525,000	)		475,000		3,000,000		(1,925,000	)		1,075,000
Developed technology		22,800,000		(19,190,000	)		3,610,000		22,800,000		(14,630,000	)		8,170,000
Intangibles, net	$	26,800,000	$	(22,557,000	)	$	4,243,000	$	26,800,000	$	(17,197,000	)	$	9,603,000

The Company recorded amortization expense for intangible assets of $5.4 million and $6.6 million for the years ended December 31, 2025 and 2024 respectively, in selling, general and administrative expenses. Intangible assets are amortized on a straight-line basis over their estimated useful lives of five years, with the exception of the developed technology intangible acquired through the acquisition of Purigen, which was amortized over fifteen years. The Purigen and Lineagen intangible assets were fully impaired during 2024. See Note 1 (Organization and Operations) for further discussion on the impairment charges impacting the Company’s intangible assets in the period. As of December 31, 2025, trade name intangibles, customer relationships, and developed technology have weighted average remaining amortization periods of 0.67 years each.

Intangible assets not subject to amortization totaled $0.1 million at December 31, 2025 and December 31, 2024 and related to the Company’s domain name.